Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma.
first line
follicular lymphoma
treatment
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
08
03
2019
entrez:
26
3
2019
pubmed:
25
3
2019
medline:
6
6
2020
Statut:
epublish
Résumé
Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma. Twenty years ago, FL was considered an indolent lymphoma with a long survival time but without a high rate of complete remission with chemotherapies. The use of rituximab has improved the response and survival of patients with this lymphoma. More recently, development of biological knowledge and use of targeted drugs have offered new perspectives, including improvement of response rates and survival with chemo-free treatment strategies. In 2019, patients have a 10-year overall survival probability of over 70%. Histological transformation to more aggressive lymphoma and treatment relapses remain a medical challenge, especially for patients relapsing within two years. This article will review the recent advances in the treatment of FL. As the use of new drugs is directly related to the development of biological aspects, we will first summarize recent advances in biological aspects of FL.
Identifiants
pubmed: 30906531
doi: 10.12688/f1000research.16686.1
pmc: PMC6426075
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
Competing interests: PF received reimbursements and fees in the past 5 years for Roche, Gilead, Janssen, Abbvie and Celgene companies. LFC has no competing interests.No competing interests were disclosed.No competing interests were disclosed.
Références
Ann Oncol. 2000 Dec;11(12):1585-90
pubmed: 11205467
Lancet. 2003 Aug 16;362(9383):516-22
pubmed: 12932382
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
Blood. 2005 Feb 15;105(4):1417-23
pubmed: 15494430
Blood. 2005 Sep 15;106(6):2169-74
pubmed: 15933054
Blood. 2005 Dec 1;106(12):3725-32
pubmed: 16123223
J Clin Oncol. 2007 May 20;25(15):1986-92
pubmed: 17420513
J Clin Oncol. 2008 Jan 20;26(3):440-6
pubmed: 18086798
Blood. 2008 Dec 15;112(13):4824-31
pubmed: 18799723
J Clin Oncol. 2009 Sep 20;27(27):4555-62
pubmed: 19652063
Lancet. 2011 Jan 1;377(9759):42-51
pubmed: 21176949
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
J Clin Oncol. 2013 Apr 20;31(12):1506-13
pubmed: 23530110
Lancet Oncol. 2014 Apr;15(4):424-35
pubmed: 24602760
J Clin Oncol. 2014 May 1;32(13):1347-55
pubmed: 24687831
J Clin Oncol. 2014 Oct 1;32(28):3096-102
pubmed: 25154829
Blood. 2015 Jan 22;125(4):658-67
pubmed: 25452615
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Lancet Oncol. 2015 Sep;16(9):1111-1122
pubmed: 26256760
Lancet Haematol. 2014 Oct;1(1):e17-27
pubmed: 27030064
J Clin Oncol. 2016 Aug 1;34(22):2575-82
pubmed: 27298402
Leuk Res. 2016 Oct;49:38-46
pubmed: 27541051
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
J Clin Oncol. 2018 Mar 1;36(7):689-696
pubmed: 29095677
Br J Haematol. 2018 Feb;180(3):365-373
pubmed: 29193021
Best Pract Res Clin Haematol. 2018 Mar;31(1):2-14
pubmed: 29452662
Lancet Oncol. 2018 Apr;19(4):549-561
pubmed: 29475724
Blood. 2018 May 31;131(22):2449-2453
pubmed: 29559480
Blood. 2018 Jul 5;132(1):49-58
pubmed: 29666118
J Clin Oncol. 2018 Aug 10;36(23):2395-2404
pubmed: 29856692
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
Lancet Oncol. 2018 Nov;19(11):1530-1542
pubmed: 30309758
Ann Oncol. 1993 Mar;4(3):182-3
pubmed: 8471549
J Clin Oncol. 1997 Mar;15(3):1110-7
pubmed: 9060552